Crowley Wealth Management Inc. Acquires New Stake in Edwards Lifesciences Co. (NYSE:EW)

Crowley Wealth Management Inc. acquired a new stake in Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 352 shares of the medical research company’s stock, valued at approximately $26,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Millstone Evans Group LLC acquired a new position in Edwards Lifesciences in the 4th quarter valued at $29,000. FSA Wealth Management LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter valued at $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Edwards Lifesciences in the 4th quarter valued at $30,000. Avior Wealth Management LLC grew its holdings in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares in the last quarter. Finally, Roble Belko & Company Inc purchased a new stake in Edwards Lifesciences in the 4th quarter valued at $46,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

EW stock opened at $70.46 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market capitalization of $41.42 billion, a P/E ratio of 10.11, a P/E/G ratio of 4.82 and a beta of 1.12. The business’s 50-day moving average is $71.42 and its two-hundred day moving average is $70.38. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, Director Steven R. Loranger sold 5,739 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the sale, the director now owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $67.96, for a total value of $645,620.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,189,770.56. This trade represents a 16.83 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 51,303 shares of company stock valued at $3,715,776 in the last quarter. Corporate insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on EW shares. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their target price for the company from $75.00 to $90.00 in a report on Thursday, January 30th. The Goldman Sachs Group upped their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Barclays upped their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Wolfe Research cut Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Finally, Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their price target for the stock from $82.00 to $90.00 in a report on Monday, December 16th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.